Anti-angiogenic therapy has proven to be useful tool for the treatment of non-small cell lung cancer (NSCLC) in the frontline setting. Excitingly, there are now anti-angiogenic agents that can be used in the second-line setting, including ramucirumab and nintedanib, as described here by Marina Garassino, MD, of the Istituto Nazionale dei Tumori, Milan, Italy. This video was recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.
Which NSCLC patients should receive chemotherapy and anti-angiogenics?
